ESMO readouts highlighted antibody‑drug conjugates and loco‑regional delivery approaches. Investigator‑led CHOPIN results showed Delcath’s regional Chemosat plus checkpoint inhibitors tripled progression‑free survival in uveal melanoma cohorts, and multiple sessions emphasized ADC combination strategies across urothelial and breast cancers. Presentations at the meeting signaled growing clinical momentum for ADCs and regionally delivered chemotherapies, prompting follow‑on collaborations and plans for registrational testing.